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The vascular endothelium is a dynamic cellular “organ” that controls passage of nutrients
into tissues, maintains the flow of blood, and regulates the trafficking of leukocytes. In
tumors, factors such as hypoxia and chronic growth factor stimulation result in endothelial
dysfunction. For example, tumor blood vessels have irregular diameters; they are fragile,
leaky, and blood flow is abnormal. There is now good evidence that these abnormalities
in the tumor endothelium contribute to tumor growth and metastasis. Thus, determining
the biological basis underlying these abnormalities is critical for understanding the patho-




Endothelial Cells, Smooth Muscle Cells,
and Basement Membrane
A continuous layer of endothelial cells (ECs)lines the heart, arterioles, capillaries, veins,
and lymphatics. Aird characterizes the endothe-
lium as a dynamic, functioning organ (Aird
2006). The endothelium is highly specialized
and varies considerably from tissue to tissue
and organ to organ. For example, the kidney’s
glomerulus is a fenestrated capillary tuft that fil-
ters blood to form urine whereas the blood–
brain barrier endothelium is characterized by
junctional proteins that restrict passage of sol-
utes into the central nervous system. Irrespec-
tive of its tissue of origin, the endothelium
performs several critical functions including
regulating the passage of nutrients, oxygen,
and other solutes from the bloodstream to the
tissues, regulating the flow of blood by main-
taining a nonthrombogenic surface, and con-
trolling the trafficking of leukocytes into and
out of the tissues.
The structure of the normal vascular endo-
thelium is hierarchical. Arteries branch to arte-
rioles, which then form thin-walled capillaries.
Smooth muscle cells (SMCs) wrap around large
vessel endothelium and provide vessel stability
and paracrine/juxtacrine cues to the underlying
ECs. SMCs also express contractile proteins
that regulate vessel diameter. The finer capilla-
ries are surrounded by perivascular cells called
pericytes that also provide vessel stability (Hir-
schi and D’Amore 1996). Genetic depletion
of PDGFB (a major pericyte growth factor) or
its receptor results in loss of pericytes, vessel
leakage, and hemorrhage (Hellström et al.
2001). All blood vessels have a proteinaceous
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basement membrane or extracellular matrix
(ECM) usually rich in collagens, laminin, and
fibronectin. The ECM provides support and
stability but can also signal through interactions
with integrins expressed on the EC surface
(Hynes 2009).
HOW NEW BLOOD VESSELS ARE FORMED
Blood vessels are dynamic structures. New
vessels are formed when needed (e.g., during
wound healing), whereas old ones are pruned
away. Neovascularization occurs by three main
processes: angiogenesis, vasculogenesis, and
intussusception. These same processes are reca-
pitulated during pathophysiological angiogene-
sis found in tumors; however, the key regulatory
pathways controlling blood vessel growth,
branching, and morphology in tumor vessels
are faulty. In addition, some of the same proc-
esses regulating blood vessel patterning and
growth during development of the embryo
reappear in tumor angiogenesis (Baudino
et al. 2002). A fourth process termed arte-
riogenesis involves an increase in the diam-
eter of preexisting arterioles that remodel and
form collaterals, but this process is not well-
described in the tumor vasculature and is not
discussed here.
Angiogenesis
In the adult, new blood vessels arise from preex-
isting ones by angiogenesis. Angiogenesis is
characterized by dissolution of the ECM, EC
mitoses, and sprouting. Vascular patterning is
controlled by gradients of angiogenic factors
that guide and unite immature endothelial tip
cells (Gerhardt et al. 2003). For example, a
VEGF/Dll4/notch axis is a key regulator of ves-
sel sprouting (Hellström et al. 2007). Surpris-
ingly, the neuronal and vascular systems share
common guidance cues (Klagsbrun and Eich-
mann 2005). An intrinsic pathway using local
expression gradients of sFLT-1 that directs
emerging sprouts away from the parent vessel
was recently proposed (Chappell et al. 2009).
After a new vessel is formed, the basement
membrane and pericytes add stability to the
nascent vascular tree. Angiogenesis is a tightly
controlled, self-regulating, reversible process.
For example, the formation of new blood vessels
has evolved so that products generated during
ECM remodeling can inhibit EC proliferation
and migration, thus fine-tuning the formation
of new vascular structures (Kalluri 2003).
Vasculogenesis
In contrast to angiogenesis, vasculogenesis
occurs mainly during development when pro-
genitor cells (angioblasts) committed to the
vascular lineage differentiate to form an imma-
ture vascular plexus in the embryo (Jin and Pat-
terson 2009). In the yolk sac, a bi-potent stem
cell called the hemangioblast is thought to dif-
ferentiate to form both hematopoietic cells
and ECs (Lacaud et al. 2004). Aggregates of me-
sodermal cells within the yolk sac form a blood
island that gives rise to ECs at the periphery and
hematopoietic cells in the center. Shared expres-
sion of a number of different markers supports
the concept that ECs and hematopoietic cells
have a common ancestor; however, unequivocal
evidence for the existence of the hemangioblast
is still debated. Strong evidence for the genera-
tion of hematopoietic cells through hemogenic
endothelium was recently presented (Lancrin
et al. 2009). Bona fide ECs for postnatal vasculo-
genesis can be isolated from the peripheral
blood of adults, but the origin of these circulat-
ing ECs remains elusive (Yoder et al. 2007;
Melero-Martin et al. 2008). Furthermore, the
role of circulating ECs in tumor angiogenesis
remains controversial.
Intussusceptive Angiogenesis
An alternative and rapid mechanism for a new
vessel to form is through intussusceptive angio-
genesis (IA). During IA, the capillary wall forms
transvascular tissue pillars and extends into the
lumen splitting the vessel on the long axis while
maintaining intact circulation (Burri et al.
2004). Because the process occurs by reorgan-
ization of existing cells, IA allows for the rapid
increase in capillary density in the developing
embryo and perhaps in tumors (Patan et al.
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2001). For example, intermittent changes in
blood flow and sheer stress in the tumor vascu-
lature may induce remodeling and IA on the
time scale of minutes (Patan et al. 1996).
Although IA does occur in the vasculature of
growing tumors, it has been largely unexplored
as a mechanism for creating new tumor blood
vessels or as a process that could be inhibited
to thwart tumor growth.
TUMOR BLOOD VESSELS APPEAR
ABNORMAL IN VIVO
It was noticed long ago that tumor blood
vessels were abnormal morphologically. Three-
dimensional scanning electron microscopy of
vascular plaster casts showed chaotic networks
of tortuous endothelium lacking the normal
hierarchical arrangement of artery-arteriole-
capillary (Warren et al. 1978; Konerding et al.
1999). Poor tumor vessel stability may be
caused by defects in pericytes, which are in
lower abundance and are loosely attached com-
pared to normal vessels (Baluk et al. 2005).
These changes in vessel stability can affect blood
flow. For example, some tumor vessels are not
perfused with blood altogether, whereas others
have chaotic blood flow that may reverse direc-
tions. New techniques have allowed for accu-
rately measuring blood flow in tumors at the
single-capillary resolution (Kamoun et al.
2010). The density of blood vessels may increase
in bursts during early tumor formation while
decreasing in larger tumors when tumor growth
outpaces the rate of blood vessel formation.
Poor tumor vessel quality rather than vessel
abundance may therefore be a better prognostic
indicator of tumor progression or perhaps
metastasis. Dvorak has nicely classified tumor
vessels into six types based on their morphology
(Nagy et al. 2009). For example, “mother ves-
sels” are greatly enlarged, tortuous, and thin-
walled, whereas “glomeruloid microvascular
proliferations” are tangles of tiny vessels with
irregular ordered pericytes and multilayered
basement membranes.
Since those first images of the tumor vascu-
lature were made in the 1970s, advances in
microscopy have allowed for images of tumor
vessels in stunning detail (McDonald and
Choyke 2003). Notably, these images confirm
morphological abnormalities at all levels of
the vascular tree: the endothelium, pericytes,
and basement membrane. Here we will only
focus on those abnormalities described specifi-
cally in the endothelium. Unless referenced oth-
erwise, the abnormalities described below can
generally be characterized as first reported by
McDonald and colleagues and are depicted in









Normal blood vessel Tumor blood vessel
Figure 1. Abnormalities in tumor endothelial cells. In a normal blood vessel (shown at left) a monolayer of endo-
thelial cells form tight junctions with one another without overlapping at the margins. In contrast, TECs branch
and sprout excessively resulting in a defective endothelial monolayer and loss of their normal barrier function.
These branches may extend across the lumen and overlap with neighboring endothelial cells. Changes in endo-
thelial shape result in intercellular gaps or holes that leak fluid, blood, and fibrin into the surrounding tissue.
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In normal tissues the ECs form a continuous
and uniform monolayer with few cytoplasmic
projections. Tumor endothelial cells (TECs)
are of irregular shape and size; they have ruffled
margins and long, fragile cytoplasmic projec-
tions extending outward and across the vessel
lumen. The tips of some branched TECs may
penetrate the lumen creating openings or small
intercellular gaps in the vessel wall. These open-
ings allow extravasated erythrocytes to pool at
the periphery of tumor blood vessels forming
“blood lakes” which are not anastomosed with
the vasculature. The appearance of tumor endo-
thelium is described as “mosaic” because of
spotty CD31 immunoreactivity in vivo (di
Tomaso et al. 2005). The reasons for this are
twofold: ultrastructural analysis of the tumor
vessel lining shows that individual TEC lack
CD31 expression and in other areas of the vessel
wall the TECs are absent altogether. Where there
are gaps between adjacent TECs, blood can
make direct contact with the exposed basement
membrane. Nearby tumor cells may also fill
these exposed gaps (Chang et al. 2000). Tumor
cells that express VE-cadherin, fill in these gaps,
and masquerade as endothelium have been
reported (Maniotis et al. 1999), but this topic
remains controversial (McDonald et al. 2000).
Large Intercellular Openings and Holes
Similar to small intercellular gaps between
neighboring TEC, larger openings (1.5 mM)
in the walls of tumor blood vessels are also visi-
ble by scanning electron microscopy. These
larger openings lack the structural features,
including the finger-like projections often ob-
served in inflamed endothelium that could
mediate their closure. Furthermore, high TEC
turnover and motility may not allow for proper
formation of intercellular junctions and base-
ment membranes resulting in these larger holes.
Transcellular holes (0.5 mM), fenestrae, and
channels are also common in the tumor vascu-
lature. Together, these small endothelial gaps
and larger openings are probably responsible
for hemorrhage and plasma leakage observed
in most tumors. Holes in the tumor vasculature
could also act as a conduit for the passage of
tumor cells into the circulation.
Abnormal Sprouts
Tumor vessels have thin cytoplasmic projec-
tions extending across the vessel lumen. These
projections resemble tip-like filopodia observed
during intussusceptive growth but they may
overlap with one another and form loose con-
nections. The origin of these sprouts may be
the oxygen seeking tip cells at the leading edge
of sprouting vessels in hypoxic regions of the
tumor microenvironment. Carmeliet and col-
leagues recently proposed a molecular basis
for these abnormal sprouts (Mazzone et al.
2009). For example, tip cells of tumor vessels
in mice haploinsufficient for the oxygen sensor
PHD2 appear quiescent and adjust their shape
and phenotype to restore oxygen supply. Molec-
ular therapies targeting PHD2 may “normalize”
tumor vessels improving perfusion while amel-
iorating the hypoxia that can promote invasion
and metastasis (Sullivan and Graham 2007).
What Are the Causes of These Abnormalities?
Tumors are caricatures of a dysfunctional
“organ.” For example, metabolic pathways are
corrupted, tumor cells deprive nearby tissues
of nutrients, there is a buildup of toxic waste
products such as lactate resulting in acidosis,
and there are areas of nonperfusion resulting
in focal regions of hypoxia. If one considers
that the vasculature is a supply line for oxygen
and nutrients but also a conduit for the removal
of waste products, then abnormalities in the
blood vessels themselves are a major contribu-
tor to the abnormal microenvironment in
tumors. Not only do cancer cells thrive in this
environment, but selection pressure created by
these microenvironmental bottlenecks may
actually contribute to their propagation (Merlo
et al. 2006).
As an example, most tumors are character-
ized by the expression of high concentrations
of VEGF-A. VEGF alone is a potent vasodilator
that can promote fluid leakage and high inter-
stitial pressures, abnormal branching morpho-
genesis, and small gaps and fissures in the
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vasculature (Nagy et al. 2007). Thus, chronic
VEGF stimulation in tumors promotes sprout-
ing and excessive branching of tip cells leading
to irregularities in the TEC monolayer and
loss of barrier function. Irregularities in the
TEC lining surrounding these vessel protru-
sions impairs blood flow resulting in hypoxia
and hypoperfusion. Tumor vessels are also
squeezed and compressed by overlying tumor
cells, which creates biomechanical tension,
strain, and changes in blood flow (Padera
et al. 2004). This chaotic pattern of blood flow
can alter endothelial shape, size, and differentia-
tion perhaps through aberrant expression of
flow-mediated transcription factors (De Val
and Black 2009). Notably, endothelial dysfunc-
tion in tumors is not a dead end. All cell types
found within the perivascular niche either in
direct contact with the endothelium or depend-
ent on soluble vascular-derived factors (e.g.,
pericytes and trafficking leukocytes) for their
growth and differentiation might be adversely
affected.
STUDIES OF ISOLATED TUMOR
ENDOTHELIAL CELLS
For many years, it was assumed that TECs were
similar to their normal counterparts irrespec-
tive of the obvious morphological abnormal-
ities of tumor blood vessels in situ. In fact, the
theoretical success of antiangiogenic (specifi-
cally antiendothelial) strategies in cancer de-
pends to some extent on TECs remaining
stabile and not altering their phenotype over
time. However, recent studies have shown that
TEC are more complex and labile than expected
challenging the assumption that TEC are nor-
mal. Collectively, these studies show morpho-
logical, pathophysiological, cytogenetic, epi-
genetic, and gene expression changes in the
TEC pool. Despite this new knowledge, overall
our understanding of TEC biology has been
hampered by several technical limitations,
which are described below.
First, a common method for isolating
“pure” populations of TECs is immunomag-
netic separation (IMS) with antibody-coated
beads. Common cell-surface markers used to
isolate TEC are CD31 (Hida et al. 2004),
ICAM-2 (Dudley et al. 2008a), and CD146 (St
Croix et al. 2000). However, these markers are
shared by endothelial cells from virtually all vas-
cular beds (capillary, venous, arterial, and lym-
phatic); thus, heterogeneity in the isolated
population of TECs is unavoidable. The fidelity
of IMS is also not 100% so contamination by
fibroblasts and tumor cells is problematic.
Diphtheria toxin has been successfully used to
eliminate human tumor cells from cultures of
mouse TECs (Arbiser et al. 1999; Hida et al.
2004). The most proficient way to ensure purity
of isolated TECs is to prepare clonal popula-
tions, but this can be challenging because ECs
plated at clonal density will often undergo sen-
escence. Laser capture microdissection (LCM)
is also used to isolate TECs but the cells cannot
be cultured. Similar to IMS, there are problems
with contaminating pericytes and tumor cells
that copurify with TECs.
Second, the conditions for culturing TECs
in vitro are not well defined. TECs may be
adapted to the tumor microenvironment (e.g.,
chaotic blood flow, acidosis, hypoxia, nutrient
deprivation), which cannot be faithfully repli-
cated in vitro. There may be unique media
requirements and combinations of growth and
attachment factors. For example, in one study,
the use of oncofetal fibronectin was necessary
to maintain the phenotype of TECs isolated
from Lewis lung carcinoma (LLC) (Allport
and Weissleder 2003). Thus, following pheno-
typic drift, TECs placed in culture may no lon-
ger resemble TECs in vivo.
Despite the challenges, several groups have
isolated and characterized (i.e., high-through-
put gene expression analyses) TECs from
human tumors and from tumors implanted in
mice. These studies typically fall into two cate-
gories: those that isolated and characterized
TECs that were never cultured, and those that
used isolated and culture expanded TECs for
their analyses. Other studies have attempted to
create or identify “TEC” lines in vitro by cultur-
ing normal ECs with tumor cell conditioned
media or by screening mouse cell lines for the
expression of markers already known to be ex-
pressed by TECs (Walter-Yohrling et al. 2004;
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Hellebrekers et al. 2007). Although there is
some value to these approaches, the use of sur-
rogates cannot substitute for isolating TECs
from the native tumor microenvironment.
Freshly Isolated Tumor Endothelial Cells That
Were Never Cultured
St. Croix published the first comprehensive
genetic screening of human TECs from malig-
nant colorectal tissues (St Croix et al. 2000).
The investigator’s used serial analysis of gene
expression (SAGE) to identify 46 transcripts
specifically elevated in TECs. Nine novel TEC
transcripts were identified and named tumor
endothelial markers (TEMs). The hope was
that TEMs might be unique to TECs and there-
fore suitable targets or markers of the tumor
vasculature. However, subsequent studies sug-
gest that some TEM expression may not be
restricted to TECs. TEMs 1 and 5 were also
found in some normal vascular beds (Seaman
et al. 2007). In one study, TEM1 was detected
in fibroblasts and perivascular cells but not
endothelium (MacFadyen et al. 2007). Another
study showed ubiquitous TEM1 expression in
developing tissues (Opavsky et al. 2001).
TEM7 expression was found in the brain (Lee
et al. 2005) and some osteosarcoma cell lines
(Halder et al. 2009). TEM8 (the anthrax toxin
receptor) is also expressed in the vasculature
of the developing corpus luteum (St Croix
et al. 2000). Despite TEM8 expression in some
normal tissues, its utility as a marker or target
in tumor vessels is still being investigated. For
example, TEM8 knockout mice showed no
effect on physiological angiogenesis in the ret-
ina or healing wounds but the growth of some
tumor types was delayed in the TEM82/2 back-
ground (Cullen et al. 2009).
SAGE or subtractive hybridization was also
used to analyze gene expression in TECs of
human brain glioma (Madden et al. 2004; Pen
et al. 2007), ovarian cancers (Buckanovich
et al. 2007; Lu et al. 2007), and breast cancers
(Parker et al. 2004; Bhati et al. 2008) isolated
by IMS or LCM. Aird has nicely collated the
transcriptional profiling results of TECs from
multiple studies and multiple tumor types
(Aird 2009). Only a few overexpressed genes
were shared by different tumors including
MMP9 (ovary and breast), HEYL (breast and
colon), and SPARC (breast and colon and
brain). The majority of genes were limited to
one tumor type or to invasive tumors. For
example, HEYL was restricted to invasive breast
tumors (Parker et al. 2004). Thus, there may be
tumor stage and tumor-type-specific differen-
ces in the TEC pool. In support of this possibil-
ity, Hoffman used phage display and found
peptides that homed to the neovasculature of
premalignant lesions but not of malignant
skin tumors (Hoffman et al. 2003). Similarly,
tumor stage and tumor site–specific (ortho-
topic vs. subcutaneous) peptides were identi-
fied in the vasculature of pancreatic tumors
(Joyce et al. 2003).
High-throughput screens to identify unique
proteins expressed on the surface of TECs have
also been used. One approach uses colloidal
silica nanoparticles to coat the luminal surface
of the endothelium followed by subcellular frac-
tionation and subtractive proteomic mapping.
Schnitzer and colleagues used this technique
and found amino peptidase-P and annexin A1
as selective targets for the lung tumor vascula-
ture (Oh et al. 2004). Furthermore, 125I-labelled
annexin A1 antibodies accumulated in the lung
tumor vasculature, destroyed tumors and pro-
longed survival in tumor-bearing rats.
Recently, epigenetic and miRNA screens
were used to further characterize TECs at the
molecular level. For example, Grover and col-
leagues found methylation silencing of the
GSTP1 and RARb2 promoters in prostate
TEC isolated by LCM (Grover et al. 2006).
Eighty-one genes were silenced in normal ECs
cultured in tumor cell–conditioned medium—
some of these genes were confirmed in TECs
isolated by LCM (Hellebrekers et al. 2007).
A regulatory miRNA (miR-296), which controls
expression of the growth factor receptors
VEGFR-2 and PFGFRb, was found elevated in
primary TECs from human brain tumors (Wür-
dinger et al. 2008). The miRNA miR-132 is ele-
vated in the endothelium of human tumors
and hemangioma where it is proposed to func-
tion as an angiogenic switch by suppressing
A.C. Dudley



















p120RasGAP leading to Ras activation and
angiogenesis stimulation (Anand et al. 2010).
Taken together, high-throughput protein and
gene arrays and more recently miRNA screens
have been used to identify unique molecular
signatures in the tumor vasculature. These stud-
ies collectively show diverse patterns of altered
gene expression from different tumor types
and stages of progression (see Table 1). How-
ever, no unique marker or factor in the tumor
vasculature has proven suitable as a durable tar-
get for antiangiogenesis therapy.
Culture Expanded TECs
Using Fresh Human Tumors
Isolation of the first primary cultures of ECs
from normal umbilical veins dramatically
increased our fundamental understanding of
EC biology (Gimbrone et al. 1974). Incredibly,
it would be almost 30 years before the first cul-
tures of TECs were isolated and culture
expanded. One of the advantages of culture
expansion is that functional in vitro assays can
be performed. For example, in one of the first
reports of successful isolation and culture of
human TECs, Allesandri and coworkers showed
that human TECs maintain their phenotype in
culture, they express growth factor receptors
and they are stimulated by typical EC mitogens
(Alessandri et al. 1999). Bussolati showed
up-regulation of angiopoietin-1, phospho-Akt
and VEGF-D in cultured TECs from renal carci-
noma—these TECs were also more resistant to
the chemotherapeutic drug vincristine (Busso-
lati et al. 2003). The same group later showed
that the Pax2 transcription factor is elevated in
TEC (Fonsato et al. 2006). Silencing Pax2
resulted in a decrease in phospho-Akt and
decreased resistance to vincristine. Notably, a
recent study found no evidence for increased
basal phospho-Akt in human hepatocellular
carcinoma TECs, but TECs were less sensitive
to 5-FU and Sorafenib (Xiong et al. 2009).
The ECs in tumors are generally classified
as being “activated” or chronically inflamed.
A good example is the expression of Thy-1 (an
adhesion receptor for leukocytes) in tumor
vessels in situ and in isolated TECs that could
mediate interactions with proinflammatory
cells or tumor cells (Dudley et al. 2008a; Jurisic
et al. 2010). Some TECs resemble high endothe-
lial venules (HEVs) often observed in inflamed
tissues in which individual ECs have a “plump
and tall” phenotype and express chemokines
and receptors that mediate leukocyte trafficking
(Hayasaka et al. 2010). These HEV-like “nests”
have been identified in breast carcinoma and
are associated with clusters of leukocytes at their
margins (Tanaka et al. 1992). Although ICAMs
1 and 2 are reportedly decreased in isolated
human TECs from colon carcinoma (Griffioen
et al. 1996), other adhesion molecules including
E-selectin (Bussolati et al. 2003) and NCAM
(Bussolati et al. 2006) are overexpressed in cul-
tured TECs from different human tumors. Con-
stitutive expression of adhesion molecules in
tumor vessels could mediate the increased trop-
ism and trafficking of proinflammatory cells
that are also proangiogenic. Adhesion molecule
expression in TECs may be induced by contact
with tumor cells (Haddad et al. 2009), but
may persist even when cells are placed in culture
suggesting a cell autonomous mechanism of
regulation independent of tumor cell–medi-
ated stimulation.
Tumor Models in Mice
Only a few laboratories have reported successful
isolation and culture expansion of mouse TECs
from tumor bearing mice (either xenografts or
spontaneous tumors). Similar to human
TECs, there are problems with contamination
by tumor cells and other cell types found in
the tumor stroma making it difficult to obtain
pure TEC cultures. Amin reported that isolated
and culture expanded TECs from implanted
melanoma and breast tumors express ErbBs 1,
2, and 4 and are stimulated to proliferate
by EGF (Amin et al. 2006). Normal ECs
from counterpart tissues did not express
EGF-R. Other studies seem to confirm EGF-R
expression by tumor blood vessels in vivo
(Baker et al. 2002; Kim et al. 2003). Growth
stimulation in the TEC pool by EGF-R ligands
may be an alternative survival pathway beyond
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Table 1. A time line of tumor endothelial cell (TEC) isolation and characterization: 41 studies of isolated tumor endothelial cells grouped by year















































































































































Note that references to “human, rat, or mouse” in the table denote species of origin for the TECs. For example, some studies listed in the table use human tumor
cell lines implanted in mice, but the isolated TECs are of mouse origin.
This table includes only those studies where TECs were interrogated following immunomagnetic separation, laser capture microdissection, in silico subcellular






































the canonical VEGF/bFGF axis. Specific inhib-
ition of EGF-R in TECs in vivo can impair
angiogenesis and growth of tumor cells that
do not express EGF-R (Amin et al. 2008).
A principle of antiangiogenesis therapies in
cancer is that the tumor endothelium is normal
and will not change over time or develop drug
resistance. However, Hida reported abnormal
centrosomes and aneuploid chromosomes in
TECs isolated from human melanoma and lip-
osarcoma implanted in mice (Hida et al. 2004).
These chromosomal abnormalities were not
clonal nor were they derived from human
genetic material incorporated into mouse chro-
mosomes. Of note, overstimulation of endothe-
lial cultures by growth factors including bFGF
and VEGF was recently reported to induce cen-
trosome duplication in ECs (Taylor et al. 2010).
On the other hand, Streubel detected primary
and secondary translocations in ECs that were
identical to those found in follicular lymphoma
suggesting either a tumor cell of origin for TECs
or sharing of DNA between tumor cells and ECs
(Streubel et al. 2004). Horizontal transfer of
genetic material via apoptotic bodies between
tumor cells and ECs has been reported (Ehnfors
et al. 2009). Loss of function of gatekeeper
genes in the stroma (e.g., p53) may also underlie
these cytogenetic abnormalities (Hill et al. 2005;
Dudley et al. 2008b).
Our laboratory has reported unusual pat-
terns of differentiation in TECs isolated from
spontaneous prostate tumors in TRAMP
(transgenic adenocarcinoma of the mouse pros-
tate) mice. For example, prostate tumor TECs
unexpectedly differentiate to form bone and
cartilage (Dudley et al. 2008a). Ectopic micro-
vascular calcification was also detected along
the capillary lumens of human prostate cancers.
Breast tumors are also characterized by microcal-
cifications in the vasculature (Tse et al. 2008).
Unexpected patterns of differentiation in tumor
vessels may arise as vascular cells (and other stro-
mal cells) coevolve with tumor cells and switch
their phenotype (Polyak et al. 2009). For exam-
ple, lineage switches and coexpression of
lymphatic, endothelial, and fibroblast markers
have been observed in the blood vessels of other
malignancies (Breiteneder-Geleff et al. 1999;
Wang et al. 2004). Pathophysiological conditions
in the tumor microenvironment including
aberrant expression of growth and differentiation
factors may control the fate, differentiation,
and mesenchymal transition of TECs (Verfaillie
2008). One surprising finding is that TECs
appear to “remember” the tumor microenviron-
ment from which they were isolated. For exam-
ple, Ghosh showed that isolated TECs fail to
reorient their actin cytoskeleton when exposed
to uniaxial cyclic strain and they display greater
traction forces in response to variations in ECM
elasticity in vitro (Ghosh et al. 2008). These re-
sults were related to high constitutive Rho and
its downstream effector ROCK in TECs. The
ECM in tumors is characterized by highly cross-
linked collagen resulting in a “stiffer” matrix that
can alter the pattern of signaling and focal adhe-
sions to the underlying endothelium (Levental
et al. 2009). TECs may be reprogrammed or
adapted to these conditions, which could
account for some of the structural and functional
abnormalities in the tumor vasculature.
TEC ABNORMALITIES MAY CONTRIBUTE
TO TUMOR PROGRESSION
The range of morphological, cellular, and
molecular abnormalities reported specifically
in TECs is broad and diverse. As already noted,
VEGF-A alone is sufficient to induce most of
the morphological changes (tortuosity, exces-
sive branching, and leakiness) observed in the
tumor vasculature. But can these abnormalities
facilitate tumor growth and progression to
metastases? One can easily imagine how fragile,
leaky vessels or gaps and holes in the vasculature
might allow tumor cells to enter the circulation
and disseminate to distant sites. For example,
deficient pericyte coverage, which can lead to
vessel leakiness and hemorrhage, is associated
with increased metastases in human cancers
and in mouse tumor models (Yonenaga et al.
2005; Xian et al. 2006). As a corollary, treatment
modalities that reverse these abnormalities
in the vasculature might prevent metastasis.
Indeed, blood vessels in LNCap-19 tumors
(derived from an androgen-independent sub-
line of LNCap) have fewer pericytes and
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increased tumor cell invasion compared to the
parental cell line (Welén et al. 2009). Similarly,
a change in TEC shape in PHD2þ/2 mice is suf-
ficient to improve oxygenation while suppress-
ing tumor invasion and metastases (Mazzone
et al. 2009). Jain has hypothesized that vessel
leakiness impairs the delivery of chemothera-
peutic drugs to the tumor site and therefore
blocking VEGF might “normalize” blood flow
and improve drug delivery (Jain 2005). In a
mouse model, a single dose of Avastin (anti-
VEGF antibodies) decreased microvessel den-
sity, vessel permeability and interstitial pressure
while intratumoral perfusion was improved
(Dickson et al. 2007). Recent clinical studies
support the concept that combining Avastin
with chemotherapy can lead to improved out-
comes in patients with advanced rectal cancer
(Willett et al. 2007).
Heterotypic interactions and cross talk
between TECs and other cell types, particularly
leukocytes mobilized from the circulation,
might also be affected by abnormalities in the
tumor vasculature. As an example, some adhe-
sion molecules may be decreased in the tumor
vasculature allowing tumors to escape immune
surveillance because of impaired interactions
between T-lymphocytes and the blood vessel
wall (Griffioen et al. 1996; Dirkx et al. 2006).
Indeed, the penetration and efficacy of primed
T cells for tumor immunotherapy was en-
hanced when proinflammatory agents that
up-regulated ICAM and VCAM in the vascula-
ture were coadministered (Garbi et al. 2004).
On the other hand, tumors resemble
“wounds that never heal” and TECs may consti-
tutively overexpress adhesion molecules for
proinflammatory cells (Dvorak 1986). Thus, a
perivascular positioning of leukocytes at the
periphery of tumor vessels is common (Dudley
et al. 2010). These proinflammatory cells ex-
press most of the endothelial survival and
matrix remodeling factors required for angio-
genesis. In one sense then, inflammation or
activation of TEC enables the conscription of
a diverse population of auxiliary cells that play
a catalytic role during angiogenesis. Further-
more, proinflammatory cells, particularly mac-
rophages, not only stimulate angiogenesis, but
they may also enable metastasis (Qian and
Pollard 2010). Because the endothelium acts a
gatekeeper controlling the egress of proinflam-
matory cells into the tissue (or tumor), blocking
specific interactions between TECs and the
immune cell infiltrate may indirectly impair
angiogenesis and metastasis. Although many
of the chemokines that control leukocyte trop-
ism are tumor cell–derived, TECs may be a
direct source for many of these chemotactic fac-
tors (Butler et al. 2010).
WHAT IS THE ORIGIN OF TUMOR
ENDOTHELIUM?
Where does the tumor endothelium come
from? The answer to this question has been
more difficult to answer than expected. For a
long time, the ECs lining tumor vessels were
thought to arise only by mitoses, sprouting, or
simple cooption of preexisting capillaries,
whereas vasculogenesis occurred only during
embryonic development. However, a distorted
variation of each of these processes probably
generates new endothelium in tumors. There
may also be additional, unexpected sources for
TECs. For example, Hendrix suggests that stem-
like tumor cells may transdifferentiate to form
endothelium (Hendrix et al. 2003). A mesen-
chymal stem cell, with properties of endothelial
cells, was shown to form pericytes and endothe-
lium in hemangioma (Khan et al. 2008).
The turnover of the endothelium in normal
tissues is low. It is estimated that only 0.1%–3%
of all ECs turn over daily but this may decline
with age (Schwartz and Benditt 1973). In
tumors, EC turnover greatly accelerates and
may be 20–2000 times the rate in normal tissues
(Hobson and Denekamp 1984). In a seminal
paper, Folkman showed that normal adult
tissues implanted in the chick chorioallantoic
membrane (CAM) did not promote neovascu-
larization whereas implanted tumors rapidly
stimulated the growth of new blood vessels
from the host (Ausprunk et al. 1975). For
the next 20 years, angiogenesis was considered
the sole or predominate source of new endothe-
lium in tumors. However, a report by Asahara in
1997 described putative circulating CD34þ/
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VEGFR-2þ endothelial progenitor cells that
could home to areas of damaged tissue and
incorporate into sites of active angiogenesis
(Asahara et al. 1997). A number of subsequent
studies identified similar cells circulating in
blood that were localized to sites of angiogenesis
in ischemic tissues and tumors (Shi et al. 1998;
Peichev et al. 2000; Lyden et al. 2001). Thus,
postnatal vasculogenesis was proposed as an
alternative route for new tumor blood vessels.
However, hematopoietic cells (e.g., monocytes)
share markers with ECs, they can be mobilized
into circulation and they also home to sites
of neovascularization following injury (Rafii
et al. 2002; Rehman et al. 2003; Case et al.
2007). Their proximity to the blood vessel and
expression of markers shared with bona fide
endothelium has created confusion and dis-
crepancies over the identification of circulating
ECs in solid tumors; especially in rodents (Ker-
bel et al. 2008; Purhonen 2008; Yoder and
Ingram 2009).
The functional differences distinguishing
hematopoietic cells from bona fide endothe-
lium are becoming clear. Yoder suggests that
only the endothelial colony forming cells
(ECFCs) can form vessel lumens, whereas hem-
atopoietic cells generally do not (Yoder 2009).
A minimum set of criteria for identifying ECFCs
in blood or tissues was also proposed by Yoder
(Yoder 2009). These same criteria should be
applied for identifying ECFCs in tumors using
rodent models. For example, bone marrow abla-
tion followed by engraftment with GFPþ mar-
row is routinely used to track circulating
“ECs” in tumors—immunohistochemistry or
FACS is used to identify the putative ECs
(Aghi and Chiocca 2005). However, these assays
provide no functional information about the
nature of the recruited circulating cell type(s).
Culture expansion and characterization (e.g.,
lumen-forming abilities when reimplanted in
mice) of GFPþ ECFCs from collagenase
digested tumor extracts would provide defini-
tive proof for the existence of a circulating EC
for tumor angiogenesis in rodents.
Recently, the vessel wall itself has been pro-
posed as a source for vascular endothelium
because it contains subpopulations of ECs
with properties similar to blood-derived ECFCs
(Ingram et al. 2005). Thus, in contrast to a bone
marrow origin, there may be a local reservoir of
highly proliferative endothelium proximal to
the tumor site. Vessel wall EPCs (VW-EPCs)
are proposed to rest in a “vasculogenic zone”
between the smooth muscle and advential layers
at the periphery of large blood vessels (Tilki
et al. 2009). No studies to date have determined
whether VW-EPCs might form the majority of
the angiogenesis response in tumors, if there
are any unique properties in VW-EPCs that
could be exploited as an antiangiogenesis strat-
egy, or if VW-EPCs might mediate vascular
rebound often observed following antiangio-
genic therapies in the clinic (Bergers and Hana-
han 2008; Ellis and Hicklin 2008).
ANTIANGIOGENIC IS NOT ALWAYS
ANTIENDOTHELIAL
Many of the original antiangiogenic strategies in
cancer were designed to be “antiendothelial” for
it makes biological sense to directly target the
“pipes” transporting blood, oxygen, and nu-
trients to a growing tumor. However, an
unexpected complication is that cell-to-cell
heterogeneity, acquired resistance, and a multi-
source origin for TECs might impinge on the
success of antiendothelial strategies. Although
the success and selectivity of antiangiogenesis
therapies in tumors depend to some extent on
there being differences in TECs compared to
their counterparts, too much variation in the
TEC pool can have the opposite effect. One
way around this problem is to target multiple
cell types simultaneously, including those now
known to play auxiliary roles during tumor
blood vessel formation. Pericytes, fibroblasts,
and other mesenchymal-lineage cells in the
stroma may be valuable indirect targets for anti-
angiogenesis in tumors (Loeffler et al. 2006);
however, hematopoietic cells, particularly those
of the myelomonocytic lineages, have recently
received great attention for this purpose (Mur-
doch et al. 2008). The role of hematopoietic lin-
eage cells in tumor angiogenesis and their
potential as targets for antiangiogenic therapies
is briefly discussed below.
Tumor Endothelial Cells



















An early clue that hematopoietic cells might
facilitate angiogenesis comes from studies in the
AML-1-deficient embryos. These mice lack
definitive hematopoiesis and show impaired
angiogenesis in the head and pericardium that
can be rescued by addition of hematopoietic
cells expressing ANG-1 (Takakura et al. 2000).
Later and in tumors, marrow-derived inflam-
matory cells including neutrophils, macro-
phages, and mast cells were shown to provide
the majority of the proangiogenic factor
MMP9 during angiogenesis (Coussens et al.
2000).
In the last 10 years, a number of studies
have confirmed the role of proinflammatory
cells in tumor angiogenesis and have identified
the molecular pathways linking inflammation
and cancer (Mantovani et al. 2008). Macro-
phages in particular appear to promote tumor
invasion, cancer initiation, and angiogenesis
(Qian and Pollard 2010). Furthermore, mono-
cytes/macrophages may create a “permissive”
environment that facilitates the seeding of
metastases at distant sites, even before tumor
cell arrival (Kaplan et al. 2005). There appear
to be tumor-specific and distinct populations
of myeloid cells recruited to tumors that release
angiogenic factors involved in matrix remodel-
ing or that stimulate endothelial cells directly
(Coffelt et al. 2010). For example, selective
depletion of neutrophils (Nozawa et al. 2006),
monocytes/macrophages (Lin et al. 2006), or
TIE-2 monocytes (De Palma et al. 2005)
impairs tumor growth and angiogenesis. Some
myeloid lineage cells (CD11bþ) are mobilized
by chemotherapies or radiation (Ahn and
Brown 2008). Furthermore, their activity in
tumors might mediate resistance to antian-
giogenic therapies by stimulating vascular
rebound. Indeed, Ahn and colleagues showed
enhancement of radiotherapy in tumors when
CD11bþ antibodies were administered systemi-
cally (Ahn et al. 2010). Finally, hematopoietic
cells may stimulate tumor blood vessel forma-
tion in other, unexpected ways. For example,




















Figure 2. A reductionist versus contemporary view of tumor endothelium. In a reductionist view, all of the endo-
thelial cells lining a tumor blood vessel are homogeneous and perhaps derived by spouting or simple cooption of
nearby vessels. In the contemporary view, TECs are heterogeneous and derived from multiple sources. A com-
posite tumor blood vessel is shown in which the endothelium may be derived by cooption or sprouting, from
endothelial progenitors localized in the vessel wall, from tumor cells masquerading as endothelial cells, from
marrow-derived endothelial progenitors, and from unexpected sources including transdifferentiated myeloid
and mesenchymal lineage cells. Plasticity and a multisource origin may contribute to tumor blood vessel abnor-
malities and allow tumor vessels to evade antiangiogenic therapies.
A.C. Dudley



















vessel formation by providing guidance and
mechanical cues that mediate anastomosis
between branching tip cells (Fantin et al.
2010). Transdifferentiation of CD45þ or
CD11bþ myeloid lineage cells into lumen-
forming endothelial-like cells in tumors was
described by Bailey (Bailey et al. 2006) and by
Yang (Yang et al. 2004), respectively.
CONCLUSIONS AND PERSPECTIVES
Since Dr. Judah Folkman’s suggestion that
tumors could be eradicated by targeting the
blood vessels feeding them, the field of antian-
giogenesis research in cancer has been met
with some surprises. For example, tumor vessels
have proven to be more complex and labile than
expected and it was not predicted that TECs
might be cytogenetically abnormal or derived
from multiple sources (Fig. 2). Furthermore,
there have been unexpected consequences of
VEGF inhibition including an up-regulation
of compensatory angiogenic pathways (Craw-
ford et al. 2009) and increased metastasis in
some mouse tumor models (Ebos et al. 2009).
Other obstacles include heterogeneity in the
vascular bed and tumor-type or stage-specific
differences in TEC that could ultimately
impinge on the effectiveness of the antiangio-
genic therapies designed to target them (Bergers
et al. 1999; Helfrich et al. 2010). There may be
unique gene expression profiles in blood vessels
from different regions of the tumor microenvi-
ronment or even in individual TECs of the same
vessel (Chi et al. 2003). In a striking example, it
was recently suggested that some tumor vessels
may lose their dependence on VEGF signaling
altogether theoretically rendering them refrac-
tory to VEGF inhibition (Nagy et al. 2010).
Our ability to isolate and better characterize
TEC from different tumors or during different
stages of tumor progression should be a valua-
ble approach for finding new targets, beyond
VEGF and its receptors, in vascular cells. On
the other hand, an innovative approach that
includes eliminating alternative cell types (e.g.,
proinflammatory cells) that may not directly
form new blood vessels, but nevertheless play
an important role during tumor angiogenesis
seems promising. Thus, TEC may be moving
targets and their phenotypic diversity or multi-
source origin might impinge on the effective-
ness of the drugs intended to target them, but
there are other approaches to consider toward
the goal of effective and durable antiangiogenic
strategies in cancer.
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